GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE
|
|
|
- Carmella Baker
- 8 years ago
- Views:
Transcription
1 Genomics in Medicine Series GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Electron Kebebew, MD, FACS
2 Outline To assess the change in thyroid cancer epidemiology To review our current knowledge on the genetic and genomic changes associated with thyroid cancer initiation and progression To consider the impact of genetic and genomic testing towards personalizing patient care
3 Illustrative Clinical Cases year old woman with a left thyroid nodule & family history of thyroid cancer 2002 A 55-year-old woman with a long history of a neck mass. 1.3 cm Thyroid nodule PTC T1aN0 DX 37 FVPTC T1N1b DX 29 38mm FNA 34yo Papillary thyroid cancer
4 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer A 55-year-old woman with a long history of a neck mass. Biopsy showed atypical cells Biopsy 8 years ago which was inconclusive. Now presents with an enlarging high right neck mass.
5 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer A 55-year-old woman with a long history of a neck mass. Biopsy showed atypical cells Biopsy 8 years ago which was inconclusive. Now presents with an enlarging high right neck mass.
6 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer A 55-year-old woman with a long history of a neck mass. Biopsy showed atypical cells Biopsy 8 years ago which was inconclusive. Now presents with an enlarging high right neck mass. 1. Total thyroidectomy and left and right central neck node dissection extending into level Right level 2, 3 and 4 lymph node dissection. 3. Left level 2, 3 and 4 lymph node dissection.
7 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer A 55-year-old woman with a long history of a neck mass. Biopsy showed atypical cells Biopsy 8 years ago which was inconclusive. Now presents with an enlarging high right neck mass. T1bN1bMx (15 of 75 nodes positive) Stage III Papillary thyroid cancer
8 Common Cancers in the US Common Types of Cancer Estimated New Cases 2013 Estimated Deaths Prostate Cancer 238,590 29, Breast Cancer 232,340 39, Lung and Bronchus Cancer 228, , Colon and Rectum Cancer 142,820 50, Melanoma of the Skin 76,690 9, Bladder Cancer 72,570 15, Non-Hodgkin Lymphoma 69,740 19, Kidney and Renal Pelvis Cancer 65,150 13, Thyroid Cancer 60,220 1, Endometrial Cancer 49,560 8,190
9 Thyroid Cancer Over 60,220 new cases will occur in 2013 in US Prevalence of thyroid nodules has increased dramatically (10% >50%) Incidence of thyroid cancer in women over McLeod et al. Lancet 2013 Histologic type Frequency Papillary 85% Follicular 7% Hürthle cell carcinoma 3% Medullary 4% Anaplastic <1% Other <1% papillary thyroid cancer
10 Thyroid Cancer Over 60,220 new cases will occur in 2013 in US Prevalence of thyroid nodules has increased dramatically (10% >50%)
11 Thyroid Cancer Over 60,220 new cases will occur in 2013 in US Prevalence of ultrasounddetected thyroid nodules ( 5 mm) Prevalence of thyroid nodules has increased dramatically (10% >50%) Sadowski et al Surgery 2013 Familial population Mazzaferri, 1993
12 Thyroid Cancer Epidemiology of Thyroid Neoplasm Over 60,220 new cases will occur in 2013 in US Prevalence of thyroid nodules has increased dramatically (10% >50%) Rate per 100, Rate of Thyroid Cancer Rate of Thyroid Nodule Rate of Inconclusive Thyroid Nodule FNA result 0 Years
13 Thyroid Cancer Epidemiology of Thyroid Neoplasm Over 60,220 new cases will occur in 2013 in US Prevalence of thyroid nodules has increased dramatically (10% >50%) Rate per 100, Rate of Thyroid Cancer Rate of Thyroid Nodule Rate of Inconclusive Thyroid Nodule FNA result 0 Years
14 Thyroid Cancer Why has the incidence increased? Overdiagnosis Davies & Welch. JAMA 2006
15 Thyroid Cancer Why has the incidence increased? Overdiagnosis Real increase in disease burden Chen et al. Cancer 2009
16 Thyroid Cancer Why has the incidence increased? Overdiagnosis Real increase in disease burden Chen et al. Cancer 2009
17 Thyroid Cancer Why has the incidence increased? Overdiagnosis Real increase in disease burden All cases Chen et al. Cancer 2009
18 Thyroid Cancer Why has the incidence increased? Overdiagnosis Real increase in disease burden Environmental Chernobyl Fukushima
19 Thyroid Cancer Why has the incidence increased? Overdiagnosis Real increase in disease burden Environmental Mathur et al. Cancer 2011 Genetic landscape of the disease Jung et al. J Clin Endocrinol Metab. 2013
20 Thyroid Cancer Over 60,220 new cases will occur in 2013 in US Multifactorial increase in the incidence of thyroid cancer across all histologies
21 Thyroid Cancer Percent of Deaths by Age Group
22 Thyroid Cancer Percent of Deaths by Age Group
23 The Cancer Genome Atlas (TCGA) Analysis of Papillary Thyroid Carcinomas Unpublished data
24 The Cancer Genome Atlas (TCGA) Analysis of Papillary Thyroid Carcinomas Unpublished data
25 Pathogenesis of thyroid cancer of follicular cell origin Shibru, et al. Curr Opin Oncol 2008
26 Pathogenesis of thyroid cancer of follicular cell origin Shibru, et al. Curr Opin Oncol 2008
27 Pathogenesis of thyroid cancer of follicular cell origin Xing M. Nat Rev. Cancer 2013
28 Pathogenesis of thyroid cancer of follicular cell origin 75% Xing M. Nat Rev. Cancer 2013
29 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer Biopsy showed atypical cells
30 Thyroid nodules FNA biopsy results Benign (80%) Malignant (<10%) Suspicious/Indeterminate (5-20%) Nondiagnostic (<10%) > 95% accurate medullary papillary follicular hürthle 5 50% risk of cancer Therapeutic thyroidectomy Diagnostic thyroidectomy
31 Thyroid nodules FNA biopsy results Benign (80%) Malignant (<10%) Suspicious/Indeterminate (5-20%) Nondiagnostic (<10%) > 95% accurate medullary papillary follicular hürthle 5 50% risk of cancer Therapeutic thyroidectomy Diagnostic thyroidectomy
32 Thyroid Nodule FNA Biopsy Studies Mean % Malignant by Histology 97% (N=8,057) Percent Malignant by Histology 10% 6% 15% 25% 62% 34% Nondiagnostic Benign Atypical FN or HC Neoplasm Susp.for Malignancy Indeterminate* Malignant Cytopathology Diagnosis *Indeterminate: atypical/flus, follicular or Hürthle cell neoplasm, and suspicious for malignancy.
33 Thyroid Nodule FNA Biopsy Studies Mean % Malignant by Histology 97% (N=8,057) Percent Malignant by Histology 10% 6% 15% 25% 62% 34% Nondiagnostic Benign Atypical FN or HC Neoplasm Susp.for Malignancy Indeterminate* Malignant Cytopathology Diagnosis *Indeterminate: atypical/flus, follicular or Hürthle cell neoplasm, and suspicious for malignancy.
34 Thyroid FNA Classification & Risk of Malignancy The Bethesda System for Reporting Thyroid Cytopathology: Implied risk of malignancy and recommended clinical management Diagnostic Category Risk of Malignancy Usual Management I. Non diagnostic or unsatisfactory NA Repeat FNAB with US guidance II. Benign 0% - 3% Clinical follow-up III. Atypia of undetermined significance or follicular lesion of undetermined significance ~5% - 15% Repeat FNAB IV. Follicular neoplasm or suspicious for a follicular neoplasm 15% - 30% Lobectomy V. Suspicious for malignancy 60% - 75% Near-total thyroidectomy or Lobectomy VI. Malignant 97% - 99% Near-total thyroidectomy
35 Marker development for thyroid cancer where are we? Patient sample Marker identification
36 Marker development for thyroid cancer where are we? Patient sample Marker identification Analytical and clinical validation FDA approval 'safe and effective' Cost-benefit analysis by CMS/Insurance Co. 'reasonable and necessary' Routine use of biomarker for patient care
37 Molecular Testing for somatic mutations Ferraz et al. J Clin Endocrinol Metab. 2011
38 Molecular Testing for somatic mutations Ferraz et al. J Clin Endocrinol Metab. 2011
39 Molecular Testing for somatic mutations Ferraz et al. J Clin Endocrinol Metab. 2011
40 Cytology category according to Bethesda Reporting System 967 of 1056 (91.6%) adequate epithelial cells and nucleic acid 50 insufficient nucleic acid 39 insufficient epithelial cells
41
42
43
44
45 Relative Mutation Rate Thyroid = 0.41 non-silent mutations per Mb Somatic mutation frequencies observed in exomes from 3,083 tumor-normal pairs. Lawrence et al. Nature 2013:499;
46 The Cancer Genome Atlas (TCGA) Analysis of Papillary Thyroid Carcinomas Driver Mutation Number of Cancer Specific Genetic Events # driver mutations % driver mutation BRAF all RAS all EIF1AX Fusions all non-braf Arm level SCNAs (non-mutated, non-fusion) Focal PTEN del TERT promoter mutations (non-mutated, non-fusion) All Unpublished data
47 Genome Wide Gene expression analysis Author Year Study cohort size Differentially expressed genes Accuracy of markers Barden et al Overall 100% Finley et al Sensitivity 91.7% specificity 95.2% Mazzanti et al and 6 gene model Overall 100% Weber et al (12 FTC 12FA) 80 genes 3 gene model Overall 96.7% Shibru, et al. Curr Opin Oncol 2008
48 Genome Wide Gene expression analysis Author Year Study cohort size Differentially expressed genes Accuracy of markers Barden et al Overall 100% Finley et al Sensitivity 91.7% specificity 95.2% Mazzanti et al and 6 gene model Overall 100% Weber et al (12 FTC 12FA) 80 genes 3 gene model Overall 96.7% Shibru, et al. Curr Opin Oncol 2008
49 T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e original article Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology Erik K. Alexander, M.D., Giulia C. Kennedy, Ph.D., Zubair W. Baloch, M.D., Ph.D., Edmund S. Cibas, M.D., Darya Chudova, Ph.D., James Diggans, Ph.D., Lyssa Friedman, R.N., M.P.A., Richard T. Kloos, M.D., Virginia A. LiVolsi, M.D., Susan J. Mandel, M.D., M.P.H., Stephen S. Raab, M.D., Juan Rosai, M.D., David L. Steward, M.D., P. Sean Walsh, M.P.H., Jonathan I. Wilde, Ph.D., Martha A. Zeiger, M.D., Richard B. Lanman, M.D., and Bryan R. Haugen, M.D. Additional FNA pass Thyroid FNA samples collected from 49 clinical sites 3,789 patients with 4,812 thyroid nodules (> 1 cm) enrolled 414 indeterminate on FNA and histologic diagnosis 51 inadequate/degraded RNA 36 excessive study site storage time 16 unavailable reference standard 265 had thyroidectomy
50 T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e original article Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology Erik K. Alexander, M.D., Giulia C. Kennedy, Ph.D., Zubair W. Baloch, M.D., Ph.D., Edmund S. Cibas, M.D., Darya Chudova, Ph.D., James Diggans, Ph.D., Lyssa Friedman, R.N., M.P.A., Richard T. Kloos, M.D., Virginia A. LiVolsi, M.D., Susan J. Mandel, M.D., M.P.H., Stephen S. Raab, M.D., Juan Rosai, M.D., David L. Steward, M.D., P. Sean Walsh, M.P.H., Jonathan I. Wilde, Ph.D., Martha A. Zeiger, M.D., Richard B. Lanman, M.D., and Bryan R. Haugen, M.D. 85 of 265 indeterminate nodules were malignant (32%) The gene expression classifier 78 of 85 as suspicious 92% Sensitivity, [84%-97%] 95% CI 52% Specificity, [44%-59%] 95% CI Overall NPV from 93% Atypia/FLUS NPV = 95% Follicular neoplasm NPV = 94% Suspicious for malignancy NPV = 85%
51 T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e original article Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology Erik K. Alexander, M.D., Giulia C. Kennedy, Ph.D., Zubair W. Baloch, M.D., Ph.D., Edmund S. Cibas, M.D., Darya Chudova, Ph.D., James Diggans, Ph.D., Lyssa Friedman, R.N., M.P.A., Richard T. Kloos, M.D., Virginia A. LiVolsi, M.D., Susan J. Mandel, M.D., M.P.H., Stephen S. Raab, M.D., Juan Rosai, M.D., David L. Steward, M.D., P. Sean Walsh, M.P.H., Jonathan I. Wilde, Ph.D., Martha A. Zeiger, M.D., Richard B. Lanman, M.D., and Bryan R. Haugen, M.D. Table 2. Performance of Gene-Expression Classifier, According to Histopathological Subtype. Histopathological Subtype No. of Nodules (%) Result with Gene- Expression Classifier Benign Total 180 (100) no. benign/no. suspicious Benign follicular nodule* 71 (39.4) 41/30 Follicular adenoma 64 (35.6) 37/27 Follicular tumor of uncertain malignant potential 11 (6.1) 5/6 Well-differentiated tumor of uncertain malignant potential 9 (5.0) 4/5 Hürthle-cell adenoma 21 (11.7) 4/17 Chronic lymphocytic thyroiditis 2 (1.1) 0/2 Hyalinizing trabecular adenoma 2 (1.1) 2/0 Malignant Total 85 (100) Papillary thyroid carcinoma 42 (49.4) 4/38 Papillary thyroid carcinoma, follicular variant 19 (22.4) 2/17 Hürthle-cell carcinoma 10 (11.8) 1/9 Follicular carcinoma 10 (11.8) 0/10 Medullary thyroid cancer 2 (2.4) 0/2 Malignant lymphoma 2 (2.4) 0/ 2
52 T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e original article Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology Erik K. Alexander, M.D., Giulia C. Kennedy, Ph.D., Zubair W. Baloch, M.D., Ph.D., Edmund S. Cibas, M.D., Darya Chudova, Ph.D., James Diggans, Ph.D., Lyssa Friedman, R.N., M.P.A., Richard T. Kloos, M.D., Virginia A. LiVolsi, M.D., Susan J. Mandel, M.D., M.P.H., Stephen S. Raab, M.D., Juan Rosai, M.D., David L. Steward, M.D., P. Sean Walsh, M.P.H., Jonathan I. Wilde, Ph.D., Martha A. Zeiger, M.D., Richard B. Lanman, M.D., and Bryan R. Haugen, M.D. Table 2. Performance of Gene-Expression Classifier, According to Histopathological Subtype. Histopathological Subtype No. of Nodules (%) Result with Gene- Expression Classifier Benign Total 180 (100) no. benign/no. suspicious Benign follicular nodule* 71 (39.4) 41/30 Follicular adenoma 64 (35.6) 37/27 Follicular tumor of uncertain malignant potential 11 (6.1) 5/6 Well-differentiated tumor of uncertain malignant potential 9 (5.0) 4/5 Hürthle-cell adenoma 21 (11.7) 4/17 Chronic lymphocytic thyroiditis 2 (1.1) 0/2 Hyalinizing trabecular adenoma 2 (1.1) 2/0 Malignant Total 85 (100) Papillary thyroid carcinoma 42 (49.4) 4/38 Papillary thyroid carcinoma, follicular variant 19 (22.4) 2/17 Hürthle-cell carcinoma 10 (11.8) 1/9 Follicular carcinoma 10 (11.8) 0/10 Medullary thyroid cancer 2 (2.4) 0/2 Malignant lymphoma 2 (2.4) 0/ 2
53 Thyroid cancer marker application: The future? Diagnostic molecular markers: Some markers beginning to be applied clinically GEC Mutation analysis Limitations in FNA and early detections of small cancers are likely to increase and result in significant healthcare expenditure.
54 Thyroid cancer marker application: The future? Diagnostic molecular markers: Some markers beginning to be applied clinically GEC Mutation analysis Limitations in FNA and early detections of small cancers are likely to increase and result in significant healthcare expenditure. Room for improvement in Detection of all/most malignant disease Avoid all/most diagnostic thyroidectomy procedures
55 Thyroid cancer marker application: The future? Diagnostic molecular markers: Some markers beginning to be applied clinically Limitations in FNA and early detections of small cancers are likely to increase and result in significant healthcare expenditure. Room for improvement in Detection of all/most malignant disease Avoid all/most diagnostic thyroidectomy procedures Genome-wide mrna expression analysis Genome-wide sequencing Genome-wide microrna expression analysis Genome-wide methylation profiling Integrated genomic analysis?
56 Thyroid cancer marker application: The future? Diagnostic molecular markers: Some markers beginning to be applied clinically Limitations in FNA and early detections of small cancers are likely to increase and result in significant healthcare expenditure. Room for improvement in Detection of all/most malignant disease Avoid all/most diagnostic thyroidectomy procedures Integrated genomic analysis? Ellis et al. J Clin Endocrinol Metab. 2013
57 Thyroid cancer marker application: The future? Diagnostic molecular markers: Some markers beginning to be applied clinically Limitations in FNA and early detections of small cancers are likely to increase and result in significant healthcare expenditure. Room for improvement in Detection of all/most malignant disease Avoid all/most diagnostic thyroidectomy procedures Integrated genomic analysis? Ellis et al. J Clin Endocrinol Metab. 2013
58 Prognostic classification systems for thyroid cancer of follicular cell origin
59 Prognostic classification systems for differentiated thyroid cancer of follicular cell origin Jukkola A, et al. Endocrine-Related Cancer, 2004
60 Is BRAF V600E a marker of thyroid cancer aggressiveness? Is BRAF V600E mutation associated with aggressive tumor phenotype? Controversial because of lack of multivariate analysis, small study cohorts, inclusion of different histologic subtypes of thyroid cancer, lack of both follow up data, different treatment approaches Xing. J Clin Endocrinol Metab, 2005
61 BRAF in thyroid cancer BRAF V600E Genotype-Phenotype association BRAF V600E mutations associated with Older age Lymph node & distant metastasis Higher TNM stage Higher AMES risk group Higher recurrence rate Kebebew et al. Ann Surg 2007
62 BRAF in thyroid cancer BRAF V600E is a risk factor for recurrence even for AMES low-risk or TNM Stage I conventional papillary thyroid cancer Kebebew et al. Ann Surg 2007
63 BRAF in thyroid cancer Xing M, et al. JAMA. 2013
64 BRAF in thyroid cancer Xing M, et al. JAMA. 2013
65 Beyond BRAF! Chronic lymphocytic thyroiditis has been linked to development of thyroid cancer PD-L1 is upregulated in papillary thyroid cancer Unpublished data
66 Beyond BRAF! Chronic lymphocytic thyroiditis has been linked to development of thyroid cancer PD-L1 is upregulated in papillary thyroid cancer Unpublished data
67 Beyond BRAF! Chronic lymphocytic thyroiditis has been linked to development of thyroid cancer PD-L1 is upregulated in papillary thyroid cancer Unpublished data
68 Illustrative Clinical Cases 63 year old woman with a left thyroid nodule & family history of thyroid cancer Biopsy showed atypical cells Mutation testing for BRAF + for V600E mutation More aggressive treatment warranted
69 Summary Molecular testing Somatic mutation and gene expression profiling are being applied with improvement in more accurate diagnosis Room for improvement What is the natural history of benign neoplasm by molecular analysis? Is it cost effective? Prognostic markers of BRAF testing Follow up Adjuvant therapy
70 Thank You
BRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.
Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,
Application of Molecular Diagnosis: Present and Future
Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
Molecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
Molecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2015 Origination: 3/2013 Next Review: 3/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
Overview 1/28/2013. Bethesda System Cytology Categories and Molecular Alterations in Thyroid FNA Specimens
Bethesda System Cytology Categories and Molecular Alterations in Thyroid FNA Specimens N. Paul Ohori, M.D. Department of Pathology University of Pittsburgh Medical Center Pittsburgh, Pennsylvania N. Paul
Writing Group for the AACE Thyroid Scientific Committee. Bernet V, Hupart KH, Parangi S and Woeber KA
Molecular Diagnostic Testing of Thyroid Nodules with Indeterminate Cytopathology Summary Highlights Writing Group for the AACE Thyroid Scientific Committee Bernet V, Hupart KH, Parangi S and Woeber KA
Thyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010
Thyroid Cancer Diagnosis and Management Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 DISCLOSURE NOTHING TO DISCLOSE in regard to financial conflict
Name of Policy: Molecular Markers in Fine Needle Aspirates of the Thyroid
Name of Policy: Molecular Markers in Fine Needle Aspirates of the Thyroid Policy #: 516 Latest Review Date: June 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule, benefits
Medical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: December 2015 Policy No: 49 Effective Date:
Molecular Pathogenesis of Thyroid Cancer
Introduction Thyroid cancer is the fastest growing cancer diagnosis in the US [1, 2] with a total of 44,670 new cases and 1,690 deaths expected in 2010 (www.cancer.gov/cancertopics/types/thyroid). From
Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules)
Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Jeffrey S. Freeman, D.O., F.A.C.O.I. Chairman, Division of Endocrinology and Metabolism Philadelphia College
BRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 4/1/2015 Most Recent Review Date (Revised): 11/24/2015 Effective Date: 2/1/2016 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
Molecular pathology of thyroid cancers
Molecular pathology of thyroid cancers Peter Lakatos 1st Department of Medicine Semmelweis University Thyroid nodules 4-7% of population with palpable nodules More frequent in women Incidence increasing
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
Classificazioni citologiche: verso uno schema internazionale unificato?
Cytology and molecular biology for thyroid nodules diagnos6c categories to clinical ac6ons From Classificazioni citologiche: verso uno schema internazionale unificato? A. Crescenzi Diagnostic categories
Thyroid cancer: In a flourish of subtypes, genes, and drivers
Thyroid cancer: In a flourish of subtypes, genes, and drivers Date : January 19, 2015 Karen Titus January 2015 Dark matter is shrinking at least in the thyroid cancer part of the universe. Until recently,
Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.31 RESEARCH ARTICLE Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma Bayu Brahma 1 *, Erwin Danil Yulian 2, Muchlis
Thyroid FNA Ancillary Studies. Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D.
Thyroid FNA Ancillary Studies Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D. What are the goals of ancillary studies of thyroid FNAs? Characterization of a known malignancy (
Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
Advances in Differentiated Thyroid Cancer
Advances in Differentiated Thyroid Cancer Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair Clinical Affairs Department of Surgery Loyola University Medical Center Thyroid Cancer classification
<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
MACHINE LEARNING FROM CONCEPT TO CLINIC: RELIABLE DETECTION OF BRAF V600E DNA MUTATIONS IN THYROID NODULES USING HIGH-DIMENSIONAL RNA EXPRESSION DATA
MACHINE LEARNING FROM CONCEPT TO CLINIC: RELIABLE DETECTION OF BRAF V600E DNA MUTATIONS IN THYROID NODULES USING HIGH-DIMENSIONAL RNA EXPRESSION DATA JAMES DIGGANS 1, SU YEON KIM 1, ZHANZHI HU 1, DANIEL
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
THYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
Standardized interpretation of fine-needle aspiration
THYROID Volume 25, Number 7, 2015 ª Mary Ann Liebert, Inc., and the American Thyroid Association DOI: 10.1089/thy.2014.0502 American Thyroid Association Statement on Surgical Application of Molecular Profiling
Nicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
330 Diagnostic Cytopathology, Vol 34, No 5 # 2006 WILEY-LISS, INC.
Does Hurthle Cell Lesion/Neoplasm Predict Malignancy More Than Follicular Lesion/Neoplasm on Thyroid Fine-Needle Aspiration? Robert T. Pu, M.D., Ph.D., 1 * Jack Yang, M.D., 2 Patricia G. Wasserman, M.D.,
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers
New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers Yuri E. Nikiforov 1#, Linwah Yip 2, Marina N. Nikiforova 1 1 Department of Pathology and Laboratory Medicine, University
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications
Open Access GENETIC TESTING IN DTC PATIENTS Rambam Maimonides Medical Journal Special Issue on Differentiated Thyroid Carcinoma Guest Editors: Ziv Gil, M.D., Ph.D. and Sagit Zolotov, M.D. Genetic Testing
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
The Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
Kidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
October is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
The incidence of thyroid cancer has increased exponentially over
FEATURE THYROID Papillary thyroid cancer: the most common endocrine malignancy JAMES C. LEE FRACS STANLEY B. SIDHU FRACS, PhD Papillary thyroid cancer has an excellent prognosis and over 90% of affected
Oncologist. The. Endocrinology. The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
The Oncologist Endocrinology The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer ADRIENNE L. MELCK, LINWAH YIP, SALLY E. CARTY University of Pittsburgh School of Medicine, Section
RESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.4.1267 BRAF Mutation is Predictive of Occult Contralateral Carcinoma in Papillary Thyroid Microcarcinoma Cases RESEARCH COMMUNICATION Preoperative BRAF Mutation
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Thyroid Cancer A Multidisciplinary Approach
Thyroid Cancer A Multidisciplinary Approach Shuvendu Sen, MD, MS, FACP Associate Program Director, Internal Medicine Residency Program Director, Medical Education Raritan Bay Medical Center, Rutgers University
Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases
PAPERS OF THE 131ST ASA ANNUAL MEETING Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases Xiao-Min Yu, MD, PhD, Yin Wan, MS, Rebecca S. Sippel, MD, FACS,
Something Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma
Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
Frozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
RADIATION INDUCED THYROID CANCER: FUNDAMENTAL AND APPLIED ASPECTS
2 Experimental Oncology 32, 2 24, 21 (September) Exp Oncol 21 32, 3, 2 24 RADIATION INDUCED THYROID CANCER: FUNDAMENTAL AND APPLIED ASPECTS M. Tronko 1,*, T. Bogdava 1, L. Voskoboynyk 1, L. Zurnadzhy 1,
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
T1799 Mutations in Thyroid Cancer - The Importance of PTC Radiation
REVIEW Endocrine-Related Cancer (2005) 12 245 262 BRAF mutation in thyroid cancer M Xing Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830
Common Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Thyroid Fine-Needle Aspiration Indications and Technique. Subcommittee members Zubair W. Baloch, MD, PhD Martha Bishop Pitman, MD
Thyroid Fine-Needle Aspiration Indications and Technique Subcommittee members Zubair W. Baloch, MD, PhD Martha Bishop Pitman, MD Thyroid FNA Indication Clinical Thyroid Nodule (s) > 1 cm? Hypo-functioning
Breast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
Original Investigation
Research Original Investigation Lack of Association of BRAF Mutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma The University of California, San Francisco, Experience Christopher
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
D. N. Poller and S. Glaysher
DOI:10.1111/cyt.12109 BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy Department of
Pediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed
Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Medical Grand Rounds December 10,2015 Christine Signore, MD ECNU Learning Objectives Discuss the epidemiology
Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
GENE EXPRESSION TESTS
MEDICAL POLICY GENE EXPRESSION TESTS Policy Number: 2016T0552G Effective Date: January 1, 2016 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION OF SERVICES...
DIAGNOSTIC USE OF MOLECULAR MARKERS IN THE EVALUATION OF THYROID NODULES
Presented at the AACE Annual Meeting & Congress, May 23-27, 2012, Philadelphia, PA Review Article DIAGNOSTIC USE OF MOLECULAR MARKERS IN THE EVALUATION OF THYROID NODULES Matthew I. Kim, MD; Erik K. Alexander,
Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health
Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public
Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma
Clinical Endocrinology (2014) 81, 282 288 doi: 10.1111/cen.12417 ORIGINAL ARTICLE Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma Yinlong Yang*,, Chengze Chen,
Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI)
Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI) D.A. Pizzuto1, S. Annunziata1, C. Brunelli2, G. Perotti1,
Thyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP WHO IS AT HIGH RISK OF HEREDITARY CANCER? Hereditary Cancer accounts for a small proportion of all cancer or approximately 5-10% THE DEVELOPMENT
Current Treatment of Papillary Thyroid Microcarcinoma
Advances in Surgery 46 (2012) 191 203 ADVANCES IN SURGERY Current Treatment of Papillary Thyroid Microcarcinoma Xiao-Min Yu, MD, PhD a, Ricardo Lloyd, MD, PhD b, Herbert Chen, MD c, * a Department of Surgery,
What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
Monitoring Clinical Stage to Improve Care
Monitoring Clinical Stage to Improve Care Stephen Dreyer, MD, FACS Cancer Liaison State Chair Nebraska Fremont, NE M. Asa Carter, CTR Manager, Accreditation and Standards American College of Surgeons Chicago,
Thyroid Cancer. What is cancer?
What is cancer? Thyroid Cancer The body is made up of hundreds of millions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly fashion. During the early years of a
Advances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
Kevin H. Hsu, MS, DO, Corrado Minimo MD, Seth Zwillenberg, MD
A Patient with Synchronous Follicular (Hurthle Cell), Papillary, and Medullary Thyroid Carcinomas: A Case Report with Literature Review on Possible Incidence and Pathogenesis Kevin H. Hsu, MS, DO, Corrado
Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival
Singapore Med J 2002 Vol 43(9) : 457-462 O r i g i n a l A r t i c l e Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival L H Y Lim, K C Soo, Y K Chong, F Gao, G S Hong,
Theories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,